Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22124553 | 1.00 | POLB (0.35) | POLBBCHEKMT2AMEN1ADRA1A | |
| SCHEMBL28891300 | 0.84 | TACR3 (0.33) | ALDH1A1 | |
| SCHEMBL28891302 | 0.84 | TACR3 (0.33) | ALDH1A1 | |
| SCHEMBL20521721 | 0.83 | PIK3CD (0.43) | KMT2AMEN1JAK2JAK1ALDH1A1 | |
| SCHEMBL20702387 | 0.80 | TACR3 (0.37) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL20702384 | 0.80 | TACR3 (0.37) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL4328443 | 0.80 | TACR3 (0.37) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL28598557 | 0.77 | DPP8 (0.35) | KMT2AMEN1 | |
| SCHEMBL22124551 | 0.77 | DPP8 (0.35) | KMT2AMEN1 | |
| SCHEMBL2773399 | 0.76 | RAB9A (0.40) | POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110475777-B | Novel pyrido [2,3-b ] indole compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210317141-A1 | OXOPYRIDO[1,2-A]PYRIMIDINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-14 | — | — | US | disclosed |
| CN-113195503-A | Oxopyrido [1,2-A ] pyrimidine compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317141-A1 | OXOPYRIDO[1,2-A]PYRIMIDINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | TYMS, UMPS, DPYD | POLB 47/4885BCHE 2401/4885KMT2A 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.